

## Subject Index

### **a**

Administrative burden 79, 112, 113,  
115, 117, 119  
Advocacy by scientists 361  
Animal model 59, 95, 98, 249, 274, 328  
Attracting the best minds 350

### **b**

Basic research 34, 42, 43, 46, 47, 50,  
55, 73, 135, 184–186, 206, 252, 287,  
295, 296, 346  
Basic tests before releasing 323  
Bicycle principle 294  
Bioinformatics 64, 104, 250, 251  
Biomimicry 263, 264  
Blockbuster drugs 56, 57  
Bouncing ideas 211–212  
Brazil 367, 373  
Bronx high school of science 356  
Bubble bias 198, 246  
Burden of disease 143, 148, 377  
Bureaucratization 11, 111, 126  
Business plan 59, 82, 302, 352

### **c**

Cell lines contamination 342  
China 41, 186, 217, 365, 366, 369,  
373, 374, 378, 380

Clinical research 46, 95, 212, 231,  
232, 241, 332, 338, 362, 374, 377, 379  
Clinical translational science award  
(CTSA) 173, 206  
Clusters of technology 369  
Commercialization 6, 12, 17, 46, 59,  
61, 66, 82, 93, 117, 205, 209, 210,  
293, 295–298, 301, 347, 348, 350  
Community engagement 205  
Comparator articles 313  
Completeness of reporting 324  
Compliance burden 78  
Computational model 285  
Computing transparency 98  
Concept of truth 310  
Concepts of evidence 359  
Conceptual evolution 248  
Consequential research 73, 230–232  
Consistency 250, 276, 324, 348  
Consolidated Standards of Reporting  
Trials (CONSORT) guidelines 339  
Continuous quality improvement 90,  
102–104, 293, 335, 342  
Convergence 32, 201, 215, 219, 220,  
226, 345, 361  
Copyright 13, 17, 117–120, 180, 297  
Corporate competence 206–210  
Credit denial 119, 124, 351

CRISPR/Cas9, 39, 153, 164, 262, 263, 334  
 Critical thinking 23, 139, 140  
 Cross-cultural collaboration 215, 216, 220  
 Cultural diversity 140, 225  
 Curiosity-driven research 24, 43, 141, 147, 183, 184, 191, 296  
 Customer acquisition 302–304, 307  
 Cutting edge 30, 253

**d**

Damage to research 94  
 Data driven 311  
 Data science 251  
 Data transparency 100  
 Debating skills 314  
 Deeper understanding 199, 255, 304  
 Direct budget impact 63  
 Direct (PRP) disclosure 12–13  
 Disruptive innovation 30, 55  
 Divergent thinking 162–163, 166  
 Diversity 139–140, 225  
 DNA double helix 25, 208, 243, 245, 274, 278, 282  
 Donabedian concepts of quality 277, 335  
 Downstream mix-up 92  
 Druggability 231, 241  
 Dysfunctional reagents 98

**e**

Early stage pipeline 305  
 Economic development 3, 5, 11, 34, 53, 56, 93, 134, 139, 188, 205, 358, 362, 367  
 Economic outcome 12  
 Effective thinking 171  
 Electronic health records 191, 192, 371  
 Elegant methodology 178, 180, 244–248, 331  
 Emotional intelligence 171

Empathy 133–135, 146, 148  
 Entrepreneurship 64, 66, 67, 378, 379  
 Environmental exposure 187  
 Environment of innovation 177  
 Epidemiologic factors 190  
 Epidemiology 51, 91, 106, 107, 183, 186, 190, 191, 194, 196, 280, 300, 359  
 Erudite entrepreneur 295  
 Eureka 235, 236, 240, 280  
 Evidence-based 283, 316, 317  
 Experimentalists 274, 281  
 Explorer 339–340

**f**

Fasori Lutheran High School 356, 357  
 FDA approval 42, 43, 62, 76, 82, 107, 113  
 Flawed design 95  
 Fraudulent research 101–102  
 Free resources 292, 293  
 Functioning prototype 31, 208, 282, 348

**g**

Generalizability 4, 91, 137, 319, 322, 359  
 Genome sequencing 28, 55, 304  
 Global networks 375–376  
 Graduate entrepreneurship 64

**h**

High-value discoveries 292  
 Humanities 25, 137, 145, 146, 149, 356  
 Human subject protection 92, 114, 115, 346, 374  
 Hyper-competition 16, 357, 362

**i**

Impact factor 5, 25, 89, 124, 137, 138, 142, 342  
 Impediment to innovation 93  
 Improving performance 224

Inclusive environment 146, 177  
 Inconsequential research 231  
 India 41, 189, 215, 217, 367, 373, 379  
 Indirect 79, 190, 349  
 Ineffectual spending 93  
 Innovation networks 347  
 Innovation slowdown 50, 72–75  
 Innovative method 6–7, 12, 15, 75, 85, 122, 134, 135, 145, 155, 184, 194, 198, 204, 226, 243, 245, 250, 260, 265, 298, 325, 371  
 Innovative universities 17, 177, 299, 331, 341, 347, 349, 362, 367, 368, 372, 377  
 Insurance reimbursement 82  
 Intellectual impact 22–25, 154  
 Intellectual property (IP) 6, 13, 14, 17, 56, 59, 82, 110, 112, 117–119, 154, 200, 205, 207, 224, 295, 297, 300, 301, 303, 305, 307, 345  
 Interdisciplinary research 221  
 International variations 373–374  
 Israel 163, 357, 368, 369, 372, 379

**j**

Journal priority list 313

**k**

Knockout mice 249, 250  
 Know how 46, 137, 145, 170, 194  
 Knowledge society 358–362, 367, 377, 378

**l**

Lack of efficacy 46, 90  
 Lasker award 116, 163, 165, 193, 253, 317, 365  
 Late stage pipeline 305  
 Law of nature 232, 268  
 Licensing intellectual property 9, 10, 40, 56, 58, 66, 118–122, 128, 139, 298, 302, 303, 341, 347, 348, 353  
 Lysenkoism 102

**m**

Management skills 292, 293  
 Managerial competence 292  
 Market competence 207  
 Material transfer agreement 14, 296, 297, 302  
 Mathematical modeling 285  
 Measuring productivity 331, 341, 353, 354, 373  
 Mentoring 169–177, 179, 181, 182, 246  
 Mentor-mentee relationship 172, 173, 180  
 Minority thought 216  
 Miscarriage of justice 94  
 Mission of life sciences 146  
 Mission of science 39, 65, 134, 137, 139, 142, 205  
 Misuse of human subjects 92  
 Mobile researcher 218, 334  
 Model or principle 268  
 Molecular and biologic entity approval 73

**n**

Narrative model 277, 282  
 National Institutes of Health (NIH) 39, 53, 134, 170, 173, 184, 223, 357  
 Negotiating for success 350  
 Nobel prize 7, 103, 151, 152, 163–165, 170, 175, 193, 216, 225, 226, 231, 237, 260, 273, 274, 313, 331, 356, 357, 367, 377  
 Non-obvious 6, 13, 23, 286, 323  
 Non-repeatable 21, 25, 30, 50, 71, 95–98, 104, 125, 166, 208, 276, 281, 282, 292, 298, 332  
 Non-reproducible 73, 90–95, 100, 101, 103, 104, 106, 164, 192, 339, 353  
 Novel methodology 245  
 Novelty 76, 312, 367

**o**

Objectivity 159, 209, 311, 323  
 Observational data 30, 268, 269  
 Observational research 232, 267,  
 281, 339  
 Observer 237, 339  
 Opioid crisis 76  
 Outcome awareness 46

**p**

Paragraph sentence 315, 316  
 Pareto principle 143, 346  
 Partnership of arguers 202–204  
 Pasteur's quadrant 54, 68  
 Patent 7, 9, 10, 13, 17, 58, 67, 73, 77,  
 117, 128, 200, 206, 214, 254, 270,  
 291, 297, 303, 305, 307, 340, 348,  
 367, 370, 377  
 Pathological science 101–102  
 Peer review 3, 62, 65, 75, 98, 104, 125,  
 140, 285, 296, 310, 326, 338, 343  
 Percentage pay line 81  
 Performance indicator 336, 341, 342  
 Performance measure 138  
 Persistence 159, 171, 185, 253  
 Peto's paradox 266, 271  
 Phase I trial 42, 60  
 Phase II trial 60  
 Phase III trial 60  
 Phase IV trial 305  
 Physical model 284  
 PI administrative burden 111,  
 112, 128  
 Pipeline momentum 305, 306  
 Pipeline of innovation 305  
 Pointers for reviewers 313  
 Pointers to sources 201  
 Policy actions 45, 348, 370  
 Practical and statistical  
 significance 136  
 Preclinical studies 47, 96  
 Predatory publishers 125, 327  
 7-4-1 principle 157

Production system 252, 253  
 Product liability 83  
 Project-based learning 224  
 Promotion and tenure 65, 93, 224,  
 340, 348  
 Proof of concept 81  
 Protection of intellectual  
 property 117–119, 295  
 Prototype development 81, 348  
 Prototype validation 282, 286, 296  
 Public health achievement 19, 41, 43,  
 44, 51, 189, 255, 256, 274, 287,  
 358, 362  
 Public health outcome 11–12, 46, 50  
 Public trust 61, 89, 93

**q**

Quality failures 90, 133

**r**

Rational drug design 265, 271  
 Recruitment of researchers 350  
 Red tape 78, 109–111  
 Regulatory burden 112–116  
 Relational competencies 171  
 Replication 31, 81, 99, 103, 125, 179,  
 185, 187, 231, 238, 253, 278, 285,  
 288, 319, 324, 339  
 Reporting deficiency 92, 95, 100, 105,  
 192, 231, 324, 332, 339, 374  
 Reproducibility 3, 31–32, 35, 89, 94,  
 97, 103, 124–126, 158, 165, 208, 226,  
 244, 335, 339, 343, 348, 353, 359,  
 363, 374  
 Reproducible results 91–94, 100, 103,  
 226, 233  
 Repurposing 229, 233–235,  
 240, 334  
 Research agenda 26, 155–158,  
 348, 354  
 Research database 201, 296  
 Research group 66, 225, 319, 328,  
 333–335, 343

- Research innovation 4–7, 10–15,  
 17, 18, 50, 57, 64, 72–78, 110, 119,  
 140, 304  
 Research Innovation Pathways to  
 Effects (RIPE) model 12–15  
 Research institute 13, 77, 206, 250,  
 332, 334, 346  
 Research laboratory 97, 103, 162,  
 333, 335, 336  
 Research partnerships 202, 347  
 Research talent 153–155, 347  
 Research targeting 8, 134–137  
 Research university 304, 334,  
 346, 367  
 Resilience 145, 159, 225  
 Resource development 346  
 Return on research funding 56, 64,  
 65, 76, 295  
 Ring of evidence 267–270, 360  
 Rous sarcoma 179, 249, 279, 288  
 Royal Library of Alexandria 217, 365  
 Rule of three 164
- S**
- Scanning nature 260–262  
 Scholarly intuition 278–281  
 Scientific awards 163, 164, 193,  
 224, 365  
 Scientific competition 366  
 Scientific creativity 152, 225  
 Scientific methodology 206  
 Scientific misconduct 101, 126, 142  
 Scientific model 4, 11, 27–29, 139,  
 179, 192, 273–282, 286, 324  
 Scientific observation 29, 286  
 Scientific opportunity 100, 153–155,  
 184, 253  
 Scientific pluralism 22–23, 35  
 Scientific productivity 9, 29, 77, 93,  
 104, 141, 205, 217, 349  
 Scientific results 6, 11, 31, 76, 106,  
 165, 209, 230, 286, 325  
 Scientific rigor 103, 104, 146  
 Scientific theories 11, 27–29, 33, 359  
 Scientific validity 91, 201  
 Scientific writing 310–312, 314–316  
 Self-replication 31, 103, 231, 285, 339  
 Serendipity 8, 198, 236–241  
 Silicon Valley 218, 221, 307, 361,  
 369–371, 379  
 Simplified representation 276  
 S&M-R&D ratio 302  
 Societal benefits 24, 37, 40, 43, 54, 55,  
 59, 76, 165, 207, 268, 354, 362  
 Societal burden 135, 184  
 Societal impact 54–56, 65, 66, 77,  
 340, 341, 354  
 Sputnik moment 83–85  
 Staged (IP) disclosure 13, 59, 139, 297  
 Startup support 348, 350–352  
 Stories 3, 87, 133, 146–147, 155, 175,  
 184, 185, 237, 238, 251, 267–269,  
 292, 293, 311, 359, 360, 369  
 Strategic priority setting 354  
 Structure and function 114, 216,  
 255, 332  
 Support for creativity 346, 347  
 Sustaining innovation 55
- T**
- Talking through 171, 204–205  
 Target journal 312, 313  
 Team science 164, 210–211, 216, 219,  
 221–225, 228, 353  
 Technology transfer 10, 13, 17, 18,  
 55, 59–62, 66, 93, 116, 208, 296, 300,  
 302–304, 307, 347, 363  
 Technology Transfer Office  
 (TTO) 10, 13, 208, 300, 302  
 Theorists 205, 230, 274, 281  
 Three-dimensional model 274,  
 284, 285  
 Trade secret 14, 17, 117, 118, 120,  
 121, 297, 298  
 Transdisciplinary research 220,  
 227, 228

Translational research 18, 19, 66, 138,  
198, 206, 213

Transparency 8, 31, 98–100,  
102–104, 126, 264, 339, 343, 345

Triangulation 32, 232, 340

Triple evidence 279–281

Triple helix 325, 328, 367, 379

Truth-in-advertising 82, 122

Turning discovery into  
technology 252

Two-dimensional model 283

## **U**

Underrepresentation 174, 175

Unexpected outlier 264–267

Unfunded research 84

Usefulness 14, 29, 54, 76, 142,  
166, 231

## **V**

Validation 32, 82, 83, 89, 97, 105,  
106, 197, 278, 281–282, 285,  
287, 288, 325

## **W**

Warburg apparatus 246, 247

Waste in research 23, 71, 85, 91–93,  
105, 109, 119, 134, 161, 166, 198,  
264, 292, 295, 332

Working prototype 286, 296



























